Promis Neurosciences Stock Alpha and Beta Analysis
| PMN Stock | USD 0.92 0.11 10.68% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as ProMIS Neurosciences. It also helps investors analyze the systematic and unsystematic risks associated with investing in ProMIS Neurosciences over a specified time horizon. Remember, high ProMIS Neurosciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to ProMIS Neurosciences' market risk premium analysis include:
Beta (0.23) | Alpha (0.40) | Risk 4.74 | Sharpe Ratio (0.09) | Expected Return (0.44) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
ProMIS |
ProMIS Neurosciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. ProMIS Neurosciences market risk premium is the additional return an investor will receive from holding ProMIS Neurosciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in ProMIS Neurosciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate ProMIS Neurosciences' performance over market.| α | -0.4 | β | -0.23 |
ProMIS Neurosciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of ProMIS Neurosciences' Buy-and-hold return. Our buy-and-hold chart shows how ProMIS Neurosciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.ProMIS Neurosciences Market Price Analysis
Market price analysis indicators help investors to evaluate how ProMIS Neurosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading ProMIS Neurosciences shares will generate the highest return on investment. By understating and applying ProMIS Neurosciences stock market price indicators, traders can identify ProMIS Neurosciences position entry and exit signals to maximize returns.
ProMIS Neurosciences Return and Market Media
The median price of ProMIS Neurosciences for the period between Thu, Aug 29, 2024 and Wed, Nov 27, 2024 is 1.09 with a coefficient of variation of 12.22. The daily time series for the period is distributed with a sample standard deviation of 0.14, arithmetic mean of 1.13, and mean deviation of 0.13. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | ProMIS Neurosciences to Showcase PMN310s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th I... | 09/12/2024 |
2 | Acquisition by Gordon Michael S of 76931 shares of ProMIS Neurosciences at 1.2228 subject to Rule 16b-3 | 09/16/2024 |
3 | Acquisition by Gordon Michael S of 16292 shares of ProMIS Neurosciences at 1.4 subject to Rule 16b-3 | 09/17/2024 |
4 | Acquisition by Shafmaster Madge K. of 70000 shares of ProMIS Neurosciences at 1.2808 subject to Rule 16b-3 | 09/23/2024 |
5 | Acquisition by Shafmaster Madge K. of 70000 shares of ProMIS Neurosciences at 1.3004 subject to Rule 16b-3 | 09/24/2024 |
6 | Acquisition by Kirwin Patrick D. of 40000 shares of ProMIS Neurosciences at 1.11 subject to Rule 16b-3 | 10/03/2024 |
7 | Acquisition by Warma Neil K of 1144122 shares of ProMIS Neurosciences at 1.15 subject to Rule 16b-3 | 10/08/2024 |
8 | ProMIS Neurosciences Inc Reports Q3 2024 GAAP EPS of 0. ... | 11/14/2024 |
9 | Acquisition by Altstiel Larry Douglas of 175000 shares of ProMIS Neurosciences at 1.0 subject to Rule 16b-3 | 11/18/2024 |
10 | ProMIS Neurosciences stock hits 52-week low at 0.91 - Investing.com | 11/20/2024 |
About ProMIS Neurosciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including ProMIS or other stocks. Alpha measures the amount that position in ProMIS Neurosciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Net Current Asset Value | 583.44 | 518.62 | Days Payables Outstanding | 363.15 | 381.3 |
ProMIS Neurosciences Upcoming Company Events
As portrayed in its financial statements, the presentation of ProMIS Neurosciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ProMIS Neurosciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of ProMIS Neurosciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of ProMIS Neurosciences. Please utilize our Beneish M Score to check the likelihood of ProMIS Neurosciences' management manipulating its earnings.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with ProMIS Neurosciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out ProMIS Neurosciences Backtesting, ProMIS Neurosciences Valuation, ProMIS Neurosciences Correlation, ProMIS Neurosciences Hype Analysis, ProMIS Neurosciences Volatility, ProMIS Neurosciences History and analyze ProMIS Neurosciences Performance. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
ProMIS Neurosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.